Estimated Enrollment: 210
Study Start Date: December 2011
Estimated Study Completion Date: December 2013
This study is not yet open for participant recruitment.
Verified on October 2011 by Novartis
Purpose
This study will assess the safety and efficacy of alisporivir plus pegylated interferon alfa2a and Ribavirin as well as boceprevir plus pegylated interferon alfa2a and Ribavirin in African American chronic hepatitis C genotype 1 patients that have never received treatment for their hepatitis C.
